Prostate Cancer

Latest News

Genetic Variants Show ‘Potential’ to Identify High-Risk Prostate Cancer | Image Credit: © Dr_Microbe -
Genetic Variants Show ‘Potential’ to Identify High-Risk Prostate Cancer

March 21st 2023

A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.

Enzalutamide plus leuprolide appears to improve metastases-free survival vs placebo plus leuprolide in patients with non-metastatic hormone-sensitive prostate cancer.
Enzalutamide/Leuprolide Improves MFS in Prostate Cancer Subtype

March 20th 2023

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who suitable to receive PSMA-based radioligand for metastatic prostate cancer.
FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

March 16th 2023

Anthony D’Amico, MD, PhD, reviewed current practices and unanswered questions surrounding radiotherapy in the realm of prostate cancer.
Expert Dissects Recent Research into Radiotherapy for Prostate Cancer

March 15th 2023

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.
Expert Charts the Changing Treatment Landscape in CRPC

March 14th 2023

Video Series
Video Interviews
Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.
The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.
The recent episode of the "Oncology Peer Review On-The-Go" podcast features Alexandra Sokolova, MD, discussing her article on germline testing and NCCN guidelines for patients with prostate cancer.
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
On this week’s podcast, Jun Gong, MD, spoke with CancerNetwork® about the potential role of plasma glutamine as a biomarker for patients with localized prostate cancer.
Oncology Peer Review On-The-Go
Latest CME Events & Activities

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy


View More

Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

View More

Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer

View More

Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care

View More

More News